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ABSTRACT
Metastatic castration resistant prostate cancer is one of the main causes of 
male cancer associated deaths worldwide. Development of resistance is inevitable 
in patients treated with anti-androgen therapies. This highlights a need for novel 
therapeutic strategies that would be aimed upstream of the androgen receptor (AR). 
Here we report that the novel small molecule anti-androgen, galeterone targets USP12 
and USP46, two highly homologous deubiquitinating enzymes that control the AR-
AKT-MDM2-P53 signalling pathway. Consequently, galeterone is effective in multiple 
models of prostate cancer including both castrate resistant and AR-negative prostate 
cancer. However, we have observed that USP12 and USP46 selectively regulate full 
length AR protein but not the AR variants. This is the first report of deubiquitinating 
enzyme targeting as a strategy in prostate cancer treatment which we show to be 
effective in multiple, currently incurable models of this disease.
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INTRODUCTION
Prostate cancer (PC) is one of the main causes of 
cancer-related mortality in men worldwide. In the early 
stages of the disease patients respond well to anti-androgen 
based therapies however, resistance invariably develops 
within approximately two years. Even in castrate resistant 
PC (CRPC) the androgen receptor (AR) signalling cascade 
remains the critical pathway. Currently, multiple novel 
second line anti-androgens have been discovered with 
abiraterone and MDV3100 (enzalutamide) introduced 
into the clinical regime. However, these therapeutics offer 
only a short life expectancy advantage and resistance to 
them is still inevitable [1]. Additionally, patients who 
express constitutively active AR variants (AR Vs) lacking 
the ligand binding domain are intrinsically resistant to 
these novel treatments similarly to patients who lose AR 
expression and rely on alternative pathways [2, 3]. This 
highlights the need for developing novel compounds that 
could target all stages of PC.
Galeterone is a first-in-class multi-target oral small 
molecule with three reported mechanisms of activity; 
CYP17 lyase inhibition, AR antagonism, and induction of 
AR degradation [4–6]. Galeterone has shown significant 
anti-tumour activity with a well-tolerated safety profile 
in patients with CRPC in phase I and II clinical studies 
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[7] including in six out of seven Phase II patients who 
were identified in a retrospective subset analysis as 
having truncated AR with C-terminal loss [7]. Previous 
in vitro studies demonstrated galeterone to be effective 
in cell lines with AR variant expression [8]. It was 
hypothesised that AR degradation, including degradation 
of the flutamide-resistant mutant AR T878A, stimulated 
by galeterone occurs via MDM2/CHIP activity [8, 9]. 
An evaluation of the kinetics of galeterone mediated 
degradation of AR demonstrated that AR V7 degradation 
requires substantially longer exposure to galeterone than 
AR FL. Additionally, galeterone was demonstrated to be 
effective against AR-negative prostate cell lines, this was 
proposed to be a consequence of eIF2α phosphorylation, 
antagonising the Mnk-eIF4E axis, and NF-κB and 
Twist1 inhibition [10]. Further studies have shown that 
abiraterone remains highly effective following galeterone 
treatment whereas enzalutamide and chemotherapy 
showed limited efficiency [11]. However, it was recently 
reported that galeterone and abiraterone might both be 
able to replace cholesterol as a substrate in cholesterolysis 
resulting in covalent hedgehog-drug conjugates activating 
hedgehog signalling in vitro, if this was also true in vivo 
it could stimulate PC progression in patients treated with 
galeterone [12].
USP12 and USP46 were initially identified as 
deubiquitinases (DUBs) targeting H2A and H2B in 
frog oocytes [13]. They are highly homologous sharing 
89% sequence identity at the protein level, with only 11 
amino acids in the whole sequence showing no degree of 
conservation, and contain a conserved bipartite nuclear 
localisation sequence (Supplementary Figure 1). Both 
enzymes require the WD40 protein, UAF1 for enzymatic 
activity with WDR20 further required to achieve the full 
enzymatic potential [14–19]. Since their identification, 
both proteins have been reported to regulate the AKT 
phosphatases, PHLPP and PHLPPL [20–22, 62], affect 
stabilisation of the cell surface T-cell receptor via 
deubiquitination of LAT and Trat1 [23] and to regulate 
the immune response following exposure to the Epstein-
Barr virus [24]. Additionally, USP12 has been linked to 
the deubiquitination of non-activated Notch resulting 
in negative regulation of the Notch pathway [25] and 
regulation of immunity responses to LPS [26]. In contrast, 
USP46 has been reported to play a role in the nervous 
system by deubiquitination of AMPA [27] and GLR-
1 [28]. Consequently, USP46 mutations and deletions 
affect behaviour in mice [29–32]. In humans, USP46 has 
also been linked to the development of depression and 
schizophrenia [33, 34].
As galeterone was shown to regulate AR and 
MDM2 stability through an unknown mechanism, in this 
manuscript we have focused on investigating the effects 
of galeterone on USP12 and USP46 deubiquitinating 
enzymes. We were able to identify a significant functional 
overlap between these two enzymes which is not 
surprising considering their high degree of homology. 
Additionally, we found that as well as inhibiting CYP17 
and antagonising AR, galeterone is able to inhibit USP12 
and USP46 enzymatic activity towards their targets 
including the AR and P53 pathway. Our data demonstrates 
a proof-of-principle for USP12 and USP46 complex 
targeting in PC and uncovers additional mechanisms of 
galeterone activity.
RESULTS
Galeterone binds to USP12 and USP46 
It has been previously reported that galeterone 
affects AR protein stability. In prostate cells AR protein 
levels are regulated by an interplay between E3 ubiquitin 
ligases and deubiquitinating enzymes with USP10 [35, 
36], USP12 [37] and USP26 [38] previously reported 
to deubiquitinate the AR. To investigate the mechanism 
behind galeterone’s regulation of AR protein stability we 
screened a panel of enzymatically active deubiquitinating 
enzymes in vitro which demonstrated that galeterone 
selectively inhibited the enzymatic activity of only two 
DUBs USP12 (IC50 2.1-3.4 µM) and USP46 (IC50 3.4-
4.2 µM) (Figure 1A). BIAcore SPR studies demonstrated 
a dose dependent binding of galeterone to USP12 and 
USP46 (Figure 1C, 1D). It is unsurprising that both of 
these enzymes were identified considering their high 
homology (Supplementary Figure 1), shared yeast 
orthologue Ubp9 [39] and the same interacting partners 
UAF1 and WDR20 [14, 15, 18, 40]. Additionally silencing 
either USP12 or USP46 expression has similar effects on 
pAKT levels, consistent with their role in deubiquitination 
of PHLPPs [20, 21].
USP12 and USP46 have a functional overlap
To validate the shared role of USP12 and USP46 
in prostate cancer cell biology we individually silenced 
both genes in PC cells and performed full transcriptome 
analysis to establish the extent of their shared functions. 
Over 40% of genes targeted by USP12 (1005/2355) 
were commonly regulated by USP46. USP46 shared 
a significant but smaller proportion of its targets with 
USP12 (24%; 1005/4227) (Figure 2A) indicating a more 
distinct function. We found a small group of genes (183) 
that were only affected when both USP12 and USP46 
were silenced together, this group most likely represents 
genes were high level of redundancy in the function 
of these enzymes requires both to be silenced for any 
effect to be observed. We also found that silencing either 
USP12 or USP46 had the same effect on reducing AR, 
MDM2 and PSA protein levels whilst silencing either 
DUB activated the AKT signalling (pAKT) (Figure 2B). 
Following the overexpression of USP46 and AR proteins 
in COS-7 cells, immunoprecipitation of AR was shown to 
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co-precipitate USP46 demonstrating interaction between 
the two proteins (Figure 2C). Additionally co-expression 
of USP46 stabilised the AR protein levels as seen in the 
input samples (Figure 2D) similarly to what we observe 
for USP12 [37]. Furthermore, overexpressed USP46 was 
able to deubiquitinate AR (Figure 2D), similarly to our 
previous observations for USP12 [37]. Consequently, 
USP46 silencing significantly affected transcript levels of 
multiple AR target genes, including KLK3 (PSA), KLK2, 
NDRG1 and UBE2C, as demonstrated through RNA 
sequencing. Similarly, in our qPCR analysis, PSA and 
TMPRSS2 levels were decreased upon both USP12 and 
USP46 silencing confirming their overlapping role in AR 
biology (Figure 2E–2I). We performed an in silico analysis 
of prostate cancer patient samples and demonstrated a 
significant correlation (0.7) between USP12 and USP46 
expression (http://cancergenome.nih.gov/) [41] (Figure 
2J). This data is consistent with the properties of these 
two highly homologous proteins, interacting with common 
protein partners, UAF1 and WDR20 [14, 15, 18, 40] 
(Supplementary Figure 1). Interestingly, both USP12 and 
USP46 affect the P53 pathway including transcript levels 
of MDM2, BAX, NOXA and FOXO-3 and AR signalling 
including expression of KLK3, KLK2 and NDRG1 
target genes [42, 43]. Consistent with a large number of 
genes being exclusively regulated by USP46 this DUB 
was observed to control multiple signalling pathways 
independently of USP12 (Figure 2K and Supplementary 
Figures 2–6). Functional overlap between USP12 and 
USP46 was confirmed in clinical samples, increase in just 
Figure 1: Galeterone binds USP12 and USP46. (A–B) IC50 curve fit values for inhibition of USP12/UAF1 (A) and USP46/UAF1 
(B) generated using the XLFit program with a 4-parameter logistical fit. Ub-AMC was used as a substrate in the enzyme inhibition reaction 
(generated by Boston Biochem). (C–D) SPR binding data using Biacore. (E) IC50 comparison for novel antiandrogens.
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one of these enzymes was predictive of shortened relapse-
free survival while increase of both transcript levels didn’t 
convey any further predictive value (Figure 2L).
Galeterone inhibits USP12 and USP46 in 
prostate cancer cells
Galeterone is a novel antiandrogen that inhibits AR 
target gene expression, including PSA (Figure 3A–3B). 
We analysed the global effects of galeterone treatment at 
GI50 9.4 µM on LNCaP PC cells by RNA sequencing. To 
investigate if galeterone controls AR and MDM2 protein 
stability via USP12 and USP46 inhibition we compared the 
PC transcriptome after galeterone treatment to siUSP12, 
siUSP46 and siUSP12/46 transcriptome. Galeterone 
treatment significantly affected transcript levels of 4944 
genes compared to 2078 genes significantly affected by 
combined USP12 and USP46 silencing. The top 10 and 
bottom 10 most affected transcripts following galeterone 
treatment (Figure 3C) and joint USP12/46 gene silencing 
(Figure 3D) are shown. Over 40% of all the genes affected 
by either USP12 silencing (Figure 3E) or USP46 silencing 
(Figure 3F) were also similarly affected following 
galeterone treatment. Approximately 50% (2431/4944) 
of the genes affected by galeterone were not overlapped 
with any of the other treatment arms (siUSP12, siUSP46 or 
siUSP12/46) (Figure 3G), highlighting the wider cellular 
consequences of galeterone treatment as its targets include 
Figure 2: USP12 and USP46 share a significant functional overlap. (A) Venn diagram of genes significantly affected (FDR 
<0.05) by 96 h of USP12 or USP46 silencing in LNCaP cells as analysed by RNA sequencing of three separate biological experiments. (B) 
Western analysis of LNCaP cell lysates following treatment with siRNA for 96 h, as indicated. (C) USP46 and AR interaction determined 
by immunoprecipitation following overexpression. (D) Deubiquitinase activity of wild type USP12 and its catalytically deficient mutant 
form (C48A USP12M [37]), and USP46 in COS-7 cells transfected with plasmids for 96 h as indicated. Cells were treated with MG-132 for 
the final 16h followed by denaturing immunoprecipitation. (E–I) Gene transcription in LNCaP cells following treatment with USP12 and 
USP46 siRNA for 96 h. Cells were grown in SDM for 72 h followed by 24 h in 10 nM DHT. (J) Correlation between USP12 and USP46 
transcript levels in PC patient samples [41]. (K) KEGG pathway analysis of genes regulated exclusively by USP46 in transcriptomic 
analysis. (L) Relapse-free survival of PC patients based on their USP12 and USP46 levels (n = 142) [41].
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CYP17 lyase inhibition, AR antagonism, and induction of 
AR degradation as well as USP12 and USP46 inhibition. 
We performed KEGG pathway analysis of the 2431 genes 
exclusively regulated by galeterone and not USP12 or 
USP46 and determined that ‘ribosome’ was the only 
pathway significantly comprised within this gene list (FDR 
4.2e-27) (Supplementary Figure 7). However, multiple 
pathways were deregulated by galeterone treatment in the 
same way as by USP12 and USP46 silencing. Galeterone, 
siUSP12 and siUSP46 all resulted in the upregulation of the 
crucial cancer associated pathway; P53 signalling (Figure 
4). Additionally galeterone and siUSP46 had the same 
effect on multiple pathways involved in carcinogenesis 
and therapy resistance including cell cycle, ribosome 
biogenesis and RNA transport, spliceosome and DNA 
regulation at multiple levels with pyrimidine metabolism, 
DNA replication, nucleotide excision repair, mismatch 
repair and homologous recombination (Supplementary 
Figure 8–16). This confirms our biochemical data and 
demonstrates that galeterone inhibits USP12 and USP46 
in PC cells.
To investigate whether the overlap between 
galeterone and USP12/46 target genes is a consequence 
of DUB enzymatic inhibition, we investigated USP 
complex transcript levels upon galeterone treatment. 
Galeterone treatment did not significantly affect USP12 
(adj. p = 0.5) while it had a slight but significant effect on 
USP46 transcript levels (log2Fold = 0.3; adj. p = 0.003). 
Figure 3: Galeterone targets USP12 and USP46 in PC cells. (A–B) Galeterone downregulates PSA mRNA and protein expression. 
LNCaP cells grown in SDM for 72 h followed by 24 h in 10 nM DHT. Cells were treated with galeterone at 9.4 uM for 72 h followed 
by western blotting (A) and qPCR (B) analysis. (C–D) Genes most affected by 72 h galeterone treatment (C) or siUSP12/USP46 (D) as 
analysed by RNA sequencing. (E–F) Venn diagrams of genes affected (FDR <0.05) by galeterone treatment compared to USP12 silencing 
(E) or USP46 silencing (F), as analysed by RNA sequencing. (G) Venn diagram showing genes affected by one or more conditions 
(galeterone treatment, siUSP12, siUSP46 or siUSP12/USP46), determined by RNA sequencing.
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Similarly galeterone inhibition did not have a significant 
effect on transcript levels of USP12 and USP46 complex 
members UAF1 (adj. p = 0.4) and WDR20 (adj. p = 0.25). 
This demonstrates that galeterone likely inhibits USP12 
and USP46 enzymatic complexes at the protein level by 
inhibiting their deubiquitinating activity.
Galeterone affects AR half-life and stability via 
USP12 and USP46 inhibition
We have demonstrated the capacity of USP12 and 
USP46 to deubiquitinate the AR (Figure 2D) [37] and 
showed their similar effect on MDM2 protein levels 
(Figure 2B) [65]. USP12 and USP46 also control AKT 
phosphorylation levels (Figure 2B) by deubiquitinating 
PHLPP and PHLPPL AKT phosphatases [20, 21]. As 
galeterone inhibits USP12 and USP46 we assessed its 
effects on each of these proteins. In AR positive, castration 
sensitive LNCaP cells galeterone treatment decreased AR 
levels and AR half-life, abolished AR target gene, PSA, 
protein levels and decreased the levels of MDM2 protein 
while stimulating AKT phosphorylation (Figure 5A). 
Similar effective reduction of full-length AR (AR FL) and 
MDM2 was observed in the AR FL and AR variant (AR 
V) positive CWR22Rv1 castrate resistant cells (Figure 
5B) with a more pronounced effect on activation of AKT 
Figure 4: USP12, USP46 and galeterone all control the P53 pathway. P53 KEGG pathway analysis comprised of genes regulated 
commonly by galeterone and at least one of the USP12/USP46 DUBs in the RNA sequencing experiments.
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(pAKT) than in the LNCaP cell line (Figure 5A). In the 
AR amplified VCaP cell line (Figure 5C) and AR negative, 
PSA negative PC3 cells (Figure 5D) similar effects were 
observed. However, no significant effect of galeterone 
was observed on constitutively active shorter AR variants 
(Figure 5B–5C). 
Galeterone effectively inhibits cell growth in AR-
dependent and AR-independent PC cell lines
Therapy resistance is the main cause of prostate 
cancer mortality. To investigate whether galeterone 
could offer a therapeutic advantage in patients who 
develop resistance to currently available treatments we 
determined the growth inhibitory effects of galeterone 
in multiple cell lines representing different stages of PC 
progression. Galeterone was highly effective in inhibiting 
castration-sensitive LNCaP cell growth, a representative 
of early stage disease (Figure 6A). Galaterone was equally 
effective in inhibiting LNCaP cell growth when cells 
were cultured in the presence of androgens or in castrate 
conditions (Supplementary Figure 17). Additionally, 
GI50 values were comparable between LNCaP androgen 
sensitive cells and LNCaP-AI androgen independent cells 
(Figure 6B) as well as LNCaP cells which had acquired 
resistance to second line anti-androgens currently used 
in the clinic, Casodex (Figure 6C) and MDV-3100 
(Figure 6D). For the AR negative PC3 prostate cancer 
cell line, established from an aggressive bone metastasis, 
galeterone was similarly effective in inhibiting cell 
growth when compared to LNCaP cells (Figure 6F). 
However, galeterone was substantially less effective in 
inhibiting growth of CWR22Rv1 and VCaP cells that 
harbour constitutively active AR variants (Figure 6E, 
6G–6H). These experiments were extended to determine 
the effects of galeterone when combined with silencing 
multiple members of the USP-AR interacting network. 
In the LNCaP cell line, silencing AR, USP12, USP46 or 
their cofactors UAF1 and WDR20 was found to enhance 
the inhibitory effects of galeterone by an average 2-fold 
when compared to SCR control (Figure 6I). Conversely, in 
the CWR22Rv1 cell line silencing AR FL alone decreased 
galeterone efficiency by 4 fold compared to SCR 
control and silencing USP12 or USP12-USP46 complex 
members had no significant effect on galeterone efficacy. 
Interestingly, improvement in galeterone GI50 efficacy was 
observed when combined with USP46 or AR V7 silencing 
suggesting that AR V7 expression conveys resistance to 
galeterone (Figure 6I). 
USP12 is unable to bind or impact on the protein 
stability of AR Vs lacking the ligand binding 
domain
To investigate whether the diminished galeterone 
efficacy in CWR22Rv1 cells was a consequence of 
inability of USP12 activity to be directed towards AR 
Vs we silenced USP12 in CWR22Rv1 cells. Following 
depletion of USP12, the level of AR FL protein was 
reduced but we failed to observe any effect of USP12 or 
USP46 depletion on AR V protein expression (Figure 7A–
7B). We reasoned that the failure for USP12 and USP46 
to impact on AR V levels may be due to an inability for 
USP and AR Vs to physically interact. We overexpressed 
USP12 alongside AR FL or clinically relevant AR V7 
in COS-7 cells and immunoprecipitated AR constructs. 
Although we were able to confirm the USP12- AR FL 
interaction we could not detect any interaction between 
USP12 and AR V7 (Figure 7D). To validate this result 
we overexpressed USP12 with AR FL, N-terminus of AR 
(AR ND) and AR N-terminus with DNA binding domain 
(AR ND-DNA BD) to localise the USP12-AR interaction. 
We found that USP12 was unable to interact with both 
AR constructs lacking the C-terminal ligand binding 
domain (Figure 7C). We speculated that this might be 
because, as we recently reported, the AR requires its 
C-terminus for ubiquitination [42] and therefore may 
require this domain for recognition by deubiquitinating 
enzymes. The requirement of the AR ligand binding 
domain to ensure an interaction between USP12 and AR 
is supported by our results in Figure 7D showing that AR 
FL is stabilised following USP12 overexpression whereas 
the AR V7 proteins levels are unaffected (Figure 7E). 
However, USP12 was still able to exert an indirect effect 
on AR Vs by controlling its phosphorylation through 
AKT activation (Figure 7F), confirming that AR Vs are 
still phosphorylated at S213 while this phosphorylation 
is most likely to be of no consequence for AR V activity 
as phosphorylation at this site reportedly decreases AR-
androgen binding and targets AR for ubiquitination by 
MDM2 [44], both processes that seem irrelevant to AR 
V biology. 
USP12 inhibition in AR V positive lines drives 
the AR V expression profile
Our data suggests that USP12 is unable to modulate 
AR V levels or activity but is capable of targeting AR 
FL. To confirm the lack of USP12 activity towards AR 
Vs we analysed transcript levels of genes preferentially 
targeted by either AR FL or AR V7 following AR FL and 
USP12 silencing in the CWR22v1 cell line (Figure 8A). 
We observed that the transcript levels of PSA, FKBP5 
and NKX3-1 (Figure 8B) increase whereas TMPRSS2, 
KLK2 and NDRG1 (Figure 8C) transcript levels decreased 
following USP12 silencing. A similar pattern of change in 
transcript levels for these genes was observed when AR 
FL was silenced (Figure 8B, 8C). This is in agreement 
with published literature where increased V7 was reported 
to regulate FKBP5 and NKX3-1 but not TMPRSS2, 
KLK2 or NDRG1 [45]. Our previous observations for the 
LNCaP cell line that express AR FL but not AR Vs have 
demonstrated that USP12 silencing causes a decrease 
in transcript expression of all the AR target genes [37] 
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supporting our data that AR Vs are not targeted by USP12 
in the AR V expressing CWR22Rv1 cell line. Additionally, 
in an androgen responsive luciferase expression system, 
we found USP12 over-expression to efficiently co-
activate AR FL transcriptional activity following DHT 
stimulation however, USP12 over-expression had no effect 
on AR V7 transcriptional activity (Figure 8D). Following 
USP12 silencing in CWR22Rv1 cells we observed only 
a marginal effect on proliferation in either androgen-
deprived or androgen-replete conditions (Figure 8E). 
Figure 5: Galeterone controls AR FL and MDM2 protein stability and AKT phosphorylation. (A–D) Cell lines were 
seeded and following 24 h incubation treated with galeterone at 9.4 µM for 72 h. After the experiment was terminated cells were lysed and 
protein levels were analysed by Western blotting. In 5D the line represents the end of the gel.
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Silencing of either AR FL and/or AR V7 in the presence 
or absence of androgen confirmed the importance of AR 
V7 in maintaining CWR22Rv1 proliferative ability in 
castrate conditions (Figure 8E). As expected, the silencing 
of USP12 or AR FL in the LNCaP cell line had similar 
effects on LNCaP proliferation (Figure 8E). 
DISCUSSION
We are first to report USP46 to be a deubiquitinating 
enzyme for AR. USP46 is highly homologous to USP12 
in sequence, NLS and UAF1 and WDR20 co-activator 
requirement [13, 14], consequently it is unsurprising that 
they would both target AR for deubiquitination. These 
two enzymes, even though very homologous with each 
other, share limited similarity with other USPs [46, 47]. In 
this manuscript we have performed global transcriptomic 
analysis of USP12 and USP46 regulated pathways in 
PC cells. We have uncovered that, in agreement with 
our biochemical data, both of these enzymes control 
AR signalling and the P53 pathway, additionally USP12 
generally overlapped in function with USP46. USP46 
however, affects more cellular transcripts than USP12 and 
consequently it has a number of cellular pathways that it 
controls exclusively of USP12 including spliceosome and 
proteasome assembly and multiple DNA pathways. To our 
Figure 6: Galeterone inhibits PC cell growth. (A–G) Cells were treated with galeterone for 96 h with treatment starting 24 h after 
seeding. GI50 was assessed using IncuCyte by live cell imaging every 6 hours. (H) Comparison of cellular GI50s, assessed by IncuCyte. 
(I) Comparison of galeterone GI50 values in cells treated with galeterone and siRNAs. Cells were seeded and treated with siRNAs as 
indicated. Following 24 hours incubation cells were treated with varying concentrations of galeterone and GI50s were assessed using 
IncuCyte. All data represents the mean of at least three independent experiments ± SEM.
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knowledge this is the first global analysis investigating the 
cellular roles of USP12 and USP46 in PC.
In this manuscript we focused on uncovering 
the molecular mechanism of galeterone’s activity. It 
has been previously reported that galeterone controls 
AR and MDM2 protein stability while the mechanism 
was not determined [8, 9]. We screened a large panel of 
deubiquitinating enzymes and discovered that galeterone 
specifically inhibited USP12 and USP46, while it had 
no effect on any other DUBs. Further analysis showed 
a significant functional overlap between galeterone 
treatment and USP12/USP46 silencing. Through inhibiting 
USP12 and USP46 enzymatic activity galeterone was able 
to inhibit cell growth even in AR negative PC models, 
highlighting the role of USP12 and USP46 in P53 and 
AKT pathways regulation [20, 21, 63, 64]. We propose a 
model in which galeterone controls AR through CYP17 
inhibition and consequences of its direct binding to AR, 
whereas USP12 and USP46 inhibition controls P53 
and AKT pathways (Supplementary Figure 18). This 
manuscript provides a proof of principle for USP12 and 
USP46 targeted inhibition in cancer therapy. Effective 
treatment efficacy in AR negative PC3 line indicates that 
this strategy may be valuable not only in prostate cancer. 
Figure 7: USP12 does not interact with AR-V. (A–B) CWR22Rv1 cells treated with siRNA for 96 h and protein expression 
evaluated by Western blotting. (C–D) Plasmids were overexpressed in COS-7 cells for 72 h followed by immunoprecipitation and Western 
blotting for the indicated proteins. (E) Plasmids were overexpressed in COS-7 cells for 72 h as indicated and Western blotting performed 
for AR FL and AR V7 proteins. (F) CWR22Rv1 cells were treated with siRNA for 96 h followed by immunoprecipitation and Western 
blotting.
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Recently, studies into USP1 inhibition have shown high 
efficacy in lung cancers including reversing cisplatin 
resistance [48–50], GBM [51], leukaemia [52] and 
osteosarcoma [53]. USP1, similarly to USP12 and USP46, 
deubiquitinates AKT phosphatases PHLPP and PHLPPL 
[54] and relies on UAF1 for its enzymatic activity, while it 
does not bind to WDR20 or any other additional proteins 
[15]. This suggests that USP12/46 inhibition could be 
explored in a similar setting. With the recent structural 
discovery of USP12-UAF1 [16, 18] and USP46-UAF1 
[19], the development of highly specific inhibitors 
targeting the USP-UAF1 interaction will be possible.
We have demonstrated galeterone to be highly 
effective in androgen sensitive, androgen independent, 
anti-androgen resistant and AR negative PC models. 
However, we observed that galeterone was substantially 
less effective in inhibiting constitutively active AR 
Vs. This might be explained by the fact that USP12 
and USP46 also have no effect on AR Vs, potentially 
because shorter AR variants are not ubiquitinated [42]. 
Consequently, even though USP12 and USP46 can 
still control AR V S213 phosphorylation levels, by 
controlling the AKT activity, this phosphorylation site 
has no effect on AR V stability or activity. This might 
explain recent results of the phase 3 clinical trial where 
galeterone was compared directly to enzalutamide in 
men with metastatic CRPC and AR-V7 expression. 
Our data are in conflict with observations made by 
Kwegyir-Afful [8] and Duo who reported that galeterone 
treatment resulted in substantial reductions in AR V 
levels in CWR22Rv1 cells. However, a similar lack of 
galeterone’s activity against AR V has been previously 
reported [9]. Our data indicates that inhibition of USP12 
and USP46 activity with galeterone, or other compounds 
may be a very effective anti-tumour strategy, however 
galeterone effects in those PC patients expressing AR V 
may be limited.
MATERIALS AND METHODS
Antibodies and plasmids
anti-AR (Santa Cruz Biotechnology; N20 clone), 
anti-H2A.Z [55], anti-MDM2 (Santa Cruz N20 and 
SMP14), anti-FLAG, anti-USP12 and anti-α-tubulin 
(Sigma), anti-PSA and anti-P53 (Dako), and anti-
ubiquitin and anti-pAKT (Santa Cruz Biotechnology) 
antibodies were included in this project. Plasmids used 
were pARE3-Luc, pCMV-β-gal [56], pFLAG-USP12 
wild type and C48A mutant [37], pHA-Ubiquitin, 
p-FLAG-His-AR, pFLAG- AR-V7 and pDEST-IRIS-HA-
FLAG-USP46 [14].
Figure 8: USP12 silencing promotes an AR V7 expression profile. (A–C) Transcript levels following treatment with USP12 
siRNA for 96 h in CWR22Rv1 grown in steroid containing media. Data are a mean of three independent experiments normalised to SCR. 
(D) Transcriptional activity using luciferase in HEK293T cells transfected with the indicated plasmids and pARE3-luc [37] for 72 h in 
steroid depleted conditions followed by addition of 10 nM DHT for 24 h where indicated. Data are a mean ± SEM of three independent 
experiments. (E) Cellular proliferation of CWR22Rv1 after 96 h in SDM ± 10 nM DHT following siRNA depletion of the indicated 
transcripts. Cellular proliferation was assessed by cell counting and data presented is the mean ± SEM of three independent experiments.
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Cell culture, transfections
LNCaP, PC3, CWR22Rv1, HEK293T and COS-
7 cells (all purchased from the ATCC); LNCaP-Cas R, 
LNCaP-MDV R and LNCaP-AI are variant cell lines 
derived in-house by serial exposure to Bicalutamide, 
MDV3100 and steroid depleted conditions, respectively 
[57] were cultured in RPMI 1640 medium with 2 mM 
L-glutamine (Invitrogen) supplemented with 10% 
(v/v) foetal calf serum (FCS) or steroid depleted serum 
(SDM) at 37° C in 5% CO2. VCaP cells kindly donated 
by Professor Guido Jenster (Erasmus Medical Centre, 
Rotterdam) were cultured in DMEM medium with 2 mM 
L-glutamine (Invitrogen) supplemented with 10% (v/v) 
foetal calf serum (FCS) or steroid depleted serum (SDM) 
at 37° C in 5% CO2. Cell lines were never maintained 
for more than 30 passages or 3 months of continuous 
culturing. As per institutional policy, cell lines were tested 
for mycoplasma on a tri-monthly basis. Transfections 
were performed using TransIT-LT1 reagent (MirusBio) 
following the manufacturer’s instructions. Luciferase 
assays were performed as previously described [37].
Immunoprecipitation (IP)
Cells were seeded at 106 cells/90-mm dish, 
transfected with 1 µg of plasmid when indicated, incubated 
for 72 h, and lysed directly into lysis buffer (50 mM Tris, 
pH 7.5, 150 mM NaCl, 0.2 mM Na3VO4, 1% Nonidet 
P-40, 1 mM PMSF, 1mM DTT, and 1 × protease inhibitors 
(Roche Applied Science)). Lysates were incubated 
with 1 µg of antibodies for 16 h at 4° C, and antibodies 
were pulled down using protein G-Sepharose beads 
(Invitrogen). For denaturing IPs, cells were subjected to 
20 µM MG132 proteasomal inhibitor treatment for the final 
16 h followed by collection into denaturing lysis buffer 
[37] prior to immunoprecipitation using Nickel beads. 
siRNA gene silencing and gene expression 
analysis
Cells were reverse transfected with siRNA using 
RNAiMax (Invitrogen) according to the manufacturer’s 
instructions and incubated in culture medium for 96 h 
prior to cell lysis. siRNA sequences were as follows 
SCR: UUCUCCGAACGUGUCACGU[dT][dT]; AR 
FL: CCAUCUUUCUGAAUGUCCU[dTdT]; USP12: 
CAGAUCUCUUCCAUAGCAU[dTdT], WDR20: CGAG 
AAAGAUCACAAGCGA[dTdT] and UAF1: CAAAUU 
GGUUCUCAGUAGA[dTdT] [57]; AR V7: GUAGUUG 
UGAGUAUCAUGA[dT][dT] and USP46: GUCUCAAU 
GGUCUGGCUGU[dT][dT]. For RNA sequencing, RNA 
was extracted using the QIAGEN RNeasy Plus Mini 
Kit and all samples were sequenced from three separate 
biological experiments using Illumina’s total stranded 
RNA prep kit with ribozero gold for library preparation 
with 100 bp paired end reads on the Illumina HiSeq 2500 
platform, performed by AROS. 
Reads were mapped to the reference human genome 
hg19 using STAR2-pass allowing up to two mismatches 
[58]. Per gene raw read counts for each sample were 
obtained using HTseq and Gencode version 19 [59]. 
Gene-level differential expression analysis was performed 
using DEseq2 [60]. P values were adjusted to control 
for the false discovery rate (FDR) using the Benjamini-
Hochberg method. Differentially expressed genes from 
each comparison were tested for functionally enriched 
pathways and gene ontology terms using GOseq with 
a gene length bias correction on pathways annotated in 
KEGG database.
Proliferation analysis
For proliferation analysis cells were seeded 24 
hours prior to treatment with either DMSO (control) 
or galeterone for 96 hours. IncuCyte measurements of 
cellular occupation of the wells were taken every 6 hours. 
Cell growth rate was normalised to the time point zero and 
additionally in a separate set of experiments cell numbers 
were counted at 96 h to assess cellular proliferation [61].
qPCR
For qPCR, RNA was extracted using Trizol 
(Invitrogen) according to manufacturer’s instruction, 
and quantified using Nanodrop. Briefly, 1 µg of RNA 
was reverse transcribed with 1U of MMLV reverse 
transcriptase, 50 ng Oligo-dT and 630 µM dNTP 
(Promega). All qPCR was performed using the relative 
quantification method on three independent biological 
experiments and each sample was loaded in triplicate. 
qRT-PCR was conducted using SYBR®Green on 384-
well optical reaction plates with the ABI 7900HT 
real-time PCR system. Results were normalised 
to HPRT1 expression. Primers were HPRT1 F: 
5′-GAACGTCTTGCTCGAGAGATGTG-3′, R: 5′-CCA 
GCAGGTCAGCAAAGAATTT-3′; KLK2 F: 5′-AGCA 
TCGAACCAGAGGAGTTCT-3′, R: 5′-TGGAGGCTCA 
CACACTGAAGA-3′; PSA F: 5′-ACTGCATCAGGAAC 
AAAAGCGT-3′, R: 5′-TGTGGGAAGCTGTGGCTGA 
C-3′; NDRG1 F: 5′-ACAACCCCCTCTTCAACTACG-3′, 
R: 5′-GCCAATAATGCTTTTCAGCCCA-3′; AR F: 5′-G 
CAAAGCCTAAAGCCAGAT-3′, R: 5′-GAGTTCATGG 
GTGGCAAAG-3′; NKX3.1 F: 5′-AGCCAGAAAGGCA 
CTTGGG-3′, R: 5′-GGCGCCTGAAGTGTTTTCA-3′; 
TMPRSS2 F: 5′-CTGCTGGATTTCCGGGTG-3′, R: 5′-T 
TCTGAGGTCTTCCCTTTCTCCT-3′; FKBP5 F: 5′-GC 
AACAGTAGAAATCCACCTG-3′, R: 5′- CTCCAGAG 
CTTTGTCAATTCC-3′; USP46 F: 5′- TCCGGGAGA 
ATGTGTTGGC -3′, R: 5′- GTGTGGCAATGCTGTGGA 
AAA -3′; USP12 F: 5′-CAGCCTTCCAGTCATTGGCA-3′, 
R: 5′-ATCAATACGGCACAGATTCCG-3′; WDR20 F: 
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5′-TGCACCAGATCTAGAACTTGAAT-3′, R: 5′-TAT 
ACTCCCAGGAGGATGACTG-3′; UAF1 F 5′-GCT 
GATTGGTATGGACCGA-3′, R: 5′-TCTGCTTCCCT 
GGGGACAG-3′; AR V7 F: 5′-AACAGAAGTACCTG-3′, 
R: 5′-TCAGGGTCTGGTCATTTTTG-3′.
Statistical analysis
All data was first tested for its Gaussian distribution. 
Normally distributed data was tested with t-test or ANOVA 
with Dunn’s multiple comparisons where more groups 
where compared.
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